Adaptimmune Therapeutics (ADAP) Prices 20.5M ADS Offering at $11/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Adaptimmune Therapeutics plc (ADAP) PT Raised to $11 at SVB Leerink
June 1, 2020 8:15 AM EDTSVB Leerink analyst Jonathan Chang raised the price target on Adaptimmune Therapeutics plc (NASDAQ: ADAP) to $11.00 (from $4.00) while maintaining a Market Perform rating.... More
Adaptimmune Therapeutics (ADAP) Announces Proposed 12.5M ADS Offering
June 1, 2020 6:12 AM EDTAdaptimmune Therapeutics plc (NASDAQ: ADAP) today announced that it intends to offer and sell 12,500,000 American Depositary Shares (ADSs) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the... More
Jones Trading Upgrades Adaptimmune Therapeutics plc (ADAP) to Buy
May 29, 2020 2:41 PM EDTJones Trading analyst Soumit Roy upgraded Adaptimmune Therapeutics plc (NASDAQ: ADAP) from Hold to Buy.
For an analyst ratings summary and ratings history on Adaptimmune Therapeutics plc click here. For more ratings news on Adaptimmune Therapeutics plc click here.
Shares of Adaptimmune Therapeutics plc closed at $4.86 yesterday.
... MoreMizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'
May 29, 2020 1:13 PM EDTMizuho Securities analyst Mara Goldstein reiterated a Neutral rating and $3.00 price target on Adaptimmune Therapeutics plc (NASDAQ: ADAP), but said ASCO data was "incrementally supportive, acceleration of Synovial Sarcoma trial."
The analyst commented, "ADAP reported a substantial data update this morning via... More
Adaptimmune (ADAP) Announces SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction, Lung, and Head and Neck Cancers
May 29, 2020 7:33 AM EDTAdaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology (ASCO) Annual Meeting. The data demonstrate durability and responses in synovial sarcoma, supporting SPEARHEAD-1 as a potential registrational trial. The ASCO presentation also describes a new response in a patient with lung cancer, and a response in a patient with head and neck cancer (reported in January).
The Company also announced new responses in the SURPASS trial, confirming the potential for... More
